Dearborn Partners LLC Makes New Investment in Structure Therapeutics Inc. (NASDAQ:GPCR)

Dearborn Partners LLC purchased a new stake in Structure Therapeutics Inc. (NASDAQ:GPCR) during the third quarter, Holdings Channel.com reports. The firm purchased 4,600 shares of the company’s stock, valued at approximately $202,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Squarepoint Ops LLC raised its position in shares of Structure Therapeutics by 4.5% in the 2nd quarter. Squarepoint Ops LLC now owns 14,449 shares of the company’s stock valued at $567,000 after purchasing an additional 617 shares during the last quarter. Assetmark Inc. grew its holdings in Structure Therapeutics by 120.0% during the third quarter. Assetmark Inc. now owns 1,318 shares of the company’s stock worth $58,000 after acquiring an additional 719 shares during the period. Sandia Investment Management LP purchased a new position in shares of Structure Therapeutics during the 2nd quarter valued at approximately $39,000. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Structure Therapeutics by 60.1% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company’s stock worth $158,000 after acquiring an additional 1,420 shares during the period. Finally, Quarry LP purchased a new position in Structure Therapeutics during the second quarter worth approximately $79,000. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Stock Down 9.3 %

Shares of GPCR opened at $34.17 on Friday. The company has a market cap of $1.95 billion, a P/E ratio of -46.18 and a beta of -3.23. Structure Therapeutics Inc. has a fifty-two week low of $26.61 and a fifty-two week high of $66.38. The firm’s 50 day moving average price is $39.44 and its 200 day moving average price is $39.83.

Wall Street Analyst Weigh In

GPCR has been the topic of several research analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $65.00 price objective on shares of Structure Therapeutics in a report on Monday, September 23rd. Morgan Stanley assumed coverage on shares of Structure Therapeutics in a research note on Monday, September 23rd. They set an “overweight” rating and a $118.00 target price on the stock. Finally, JMP Securities lowered their price target on Structure Therapeutics from $91.00 to $86.00 and set a “market outperform” rating for the company in a report on Friday, August 9th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $86.80.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.